Cefepime-enmetazobactam: first approved cefepime-β- lactamase inhibitor combination for multi-drug resistant Enterobacterales. [PDF]
Future MicrobiolCefepime-enmetazobactam is a β-lactam/β-lactamase inhibitor (BL/BLI) combination that has demonstrated potent activity against extended spectrum beta-lactamase (ESBL)-producing Enterobacterales, recently approved by the US FDA for the treatment of ...
Bhowmick T +6 more
europepmc +5 more sources
Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians [PDF]
Pharmaceuticals, 2022 Bacterial resistance mechanisms are continuously and rapidly evolving. This is particularly true for Gram-negative bacteria. Over the last decade, the strategy to develop new β-lactam/β-lactamase inhibitors (BLs/BLIs) combinations has paid off and ...
Luigi Principe +11 more
doaj +3 more sources
Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia. [PDF]
Antimicrobial Agents and Chemotherapy, 2020 Cefepime-enmetazobactam is a novel β-lactam-β-lactamase inhibitor combination with broad-spectrum antimicrobial activity against a range of multidrug-resistant This agent is being developed for a range of serious hospital infections. An understanding of
Barth, Philip +19 more
core +5 more sources
Bicyclic Boronate β‐Lactamase Inhibitors: The Present Hope against Deadly Bacterial Pathogens [PDF]
Advanced Therapeutics, Volume 4, Issue 5, May 2021., 2021 This article highlights the therapeutic potential of recently developed bicyclic boronate inhibitors, such as taniborbactam (VNRX‐5133), VNRX‐7145, and QPX‐7728, for restoring the efficacy of β‐lactam antibiotics against multi‐drug resistant bacteria having distinct resistance mechanisms.
Emilio Lence +1 more
wiley +3 more sources
Cefepime-Enmetazobactam: a novel β-Lactam/β-Lactamase inhibitor combination for complicated urinary tract infections [PDF]
International Journal of Basic & Clinical PharmacologyComplicated urinary tract infections (cUTIs) represent a significant global health challenge, particularly with the rising prevalence of extended-spectrum β-lactamase (ESBL)-producing pathogens.
Balaji, Vikram +4 more
core +3 more sources
How Clavulanic Acid Inhibits Serine β‐Lactamases [PDF]
ChemBioChem, Volume 25, Issue 22, November 18, 2024.Inhibition of serine β‐lactamases by clavulanic acid occurs via a bifurcating mechanism. The formation of an acyl‐enzyme complex may be followed by hydrolysis, or oxazolidine ring opening and subsequent decarboxylation to give more stable species. Further fragmentation is slow and is less likely to be biologically relevant in inhibition.
Pauline A. Lang +6 more
wiley +3 more sources
CEFEPIME/ENMETAZOBACTAM: Physicochemical Stability of a Novel β-Lactam/β-Lactamase Inhibitor Combination in Syringes and Elastomeric Devices [PDF]
AntibioticsBackground: Cefepime/enmetazobactam (FEP/META) is a novel fixed-dose β-lactam/β-lactamase inhibitor combination. The objective was to study the physicochemical stability of the approved daily dose in polypropylene syringes and elastomeric devices over a ...
Akim Chayem +9 more
doaj +2 more sources
Journal of Global Antimicrobial Resistance: Objectives: This study was performed to investigate the activity of the novel ß-lactam/ß-lactamase inhibitor combination cefepime/enmetazobactam, against recently circulating Enterobacterales isolates from Europe from 2019 to 2021. Methods: A total of
Ian Morrissey +7 more
doaj +3 more sources
Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications [PDF]
Current Therapeutic ResearchObjective: This analysis aimed to provide a mechanistic understanding and an evaluation of the clinical relevance of pharmacokinetic drug-drug interactions (DDIs) associated with drugs approved by the Food and Drug Administration in 2024.
Jingjing Yu, MD, PhD +4 more
doaj +2 more sources
Amrita Journal of MedicineCefepime plus enmetazobactam represents a breakthrough novel combination of a β-lactam antibiotic and a β-lactamase inhibitor, which demonstrates extensive antibacterial activity against a wide range of both gram-positive and gram-negative bacteria.
Raja Chakraverty +2 more
doaj +2 more sources